A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma

Trial Profile

A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Vinorelbine (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Acronyms VIM
  • Most Recent Events

    • 07 Apr 2017 Planned End Date changed from 1 Sep 2019 to 1 Dec 2018.
    • 07 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Mar 2018.
    • 23 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top